Awk 1121
Vendor:
First CVE: Feb 13, 2017 · Active for 9 years
2
Total CVEs
More Total CVEs than 49% of tracked products
2.0
Avg CVEs / Year
Higher CVE frequency than 60% of tracked products
8.3
Avg CVSS
Higher Avg CVSS than 73% of tracked products
0.0%
KEV Rate
Bottom 1%
Trends Over Time
The number and severity of CVEs published that impact Awk 1121 over time
Volume of CVEsAvg CVSS Base Score
First CVE
Feb 13, 2017
9 years ago
Most Recent CVE
Feb 13, 2017
3,449 days ago
CVE Severity & Scoring
Awk 11212 CVEs
50%
50%
All CVEs352,708 CVEs
45%
40%
11%
MediumCritical
Attack Vector
Local0 (0.0%)
Network2 (100.0%)
Unknown0 (0.0%)
Physical0 (0.0%)
Adjacent Network0 (0.0%)
Attack Complexity
Low2 (100.0%)
High0 (0.0%)
Unknown0 (0.0%)
User Interaction
None2 (100.0%)
Unknown0 (0.0%)
Required0 (0.0%)
Privileges Required
Low1 (50.0%)
High0 (0.0%)
None1 (50.0%)
Unknown0 (0.0%)
Top CVEs
Signals from CVEs in this product scope (2 CVEs).
2 CVEs · Highest risk first
| CVE | Published | CVSS | Risk | KEV | Exploit |
|---|---|---|---|---|---|
CVE-2016-8363CRITICAL An issue was discovered in Moxa OnCell OnCellG3470A-LTE, AWK-1131A/3131A/4131A Series, AWK-3191 Series, AWK-5232/6232 Series, AWK-1121/1127 Series, WAC-1001 V2 Series, WAC-2004 Ser | Feb 13, 2017 | 10.0 | 29 | NO | NO |
CVE-2016-8362MEDIUM An issue was discovered in Moxa OnCell OnCellG3470A-LTE, AWK-1131A/3131A/4131A Series, AWK-3191 Series, AWK-5232/6232 Series, AWK-1121/1127 Series, WAC-1001 V2 Series, WAC-2004 Ser | Feb 13, 2017 | 6.5 | 17 | NO | NO |
Exploit Exposure
Signals from CVEs in this product scope (2 CVEs).
CISA KEV
0 CVEs
0.0% of CVEs· Bottom 1%
Metasploit
0 CVEs
0.0% of CVEs· Bottom 1%
Nuclei
0 CVEs
0.0% of CVEs· Bottom 1%
ExploitDB
0 CVEs
0.0% of CVEs· Bottom 1%
Social Chatter
Signals from CVEs in this product scope (2 CVEs).
Media Mentions
Signals from CVEs in this product scope (2 CVEs).
Top CNAs Publishing CVEs For Awk 1121
Top CWEs
Versions
No cataloged versions.